Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Oct 1;14(5):839-842.
doi: 10.21037/hbsn-2025-393. Epub 2025 Sep 26.

Durvalumab plus cisplatin and gemcitabine in advanced biliary tract cancer: can we do it better?

Margherita Rimini  1   2 , Andrea Casadei-Gardini  1   2
Affiliations
Editorial

Durvalumab plus cisplatin and gemcitabine in advanced biliary tract cancer: can we do it better?

Margherita Rimini et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Cholangiocarcinoma; durvalumab; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-393/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81. 10.1056/NEJMoa0908721 - DOI - PubMed
    1. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid 2022;1:EVIDoa2200015. - PubMed
    1. Oh DY, He AR, Bouattour M, et al. Durvalumab plus gemcitabine and cisplatin for advanced biliary tract cancer: updated overall survival from TOPAZ-1. Lancet Gastroenterol Hepatol 2024;9:694-704. 10.1016/S2468-1253(24)00095-5 - DOI - PubMed
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019;381:1535-46. 10.1056/NEJMoa1910836 - DOI - PubMed
    1. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 2020;367:eaax0182. 10.1126/science.aax0182 - DOI - PMC - PubMed